Company newsForm 8-K

AbCellera Biologics ABCL

AbCellera Biologics prices $200 million offering of common shares and pre-funded warrants

AbCellera Biologics said gross proceeds are expected to be approximately $200 million, before underwriting discounts and offering expenses.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

On August 12, 2026, AbCellera Biologics priced an underwritten offering of 17,435,897 common shares at $9.75 per share, plus pre-funded warrants for up to 3,076,926 shares.

It expects net proceeds of approximately $187 million and closing on or about August 14, 2026, subject to customary closing conditions. It intends to use the proceeds for its internal pipeline including lead clinical program ABCL635 and for working capital and general corporate purposes.

Key facts

Gross proceeds expected
Approximately $200 million
Net proceeds expected
Approximately $187 million
Expected closing
August 14, 2026, subject to customary closing conditions

All ABCL news

Source: Form 8-K filed August 13, 2026. The company's release as filed with the SEC.

Written by GetSignal with AI from the company's SEC filing. How we make news

Not investment advice.

More company news

AbCellera Biologics first, then the newest

All company news